753.55
-1.96 (-0.26%)
| Previous Close | 755.51 |
| Open | 757.31 |
| Volume | 676,321 |
| Avg. Volume (3M) | 1,008,519 |
| Market Cap | 79,866,830,848 |
| Price / Earnings (TTM) | 18.05 |
| Price / Earnings (Forward) | 16.86 |
| Price / Sales | 5.61 |
| Price / Book | 2.49 |
| 52 Weeks Range | |
| Earnings Date | 30 Jan 2026 |
| TTM Dividend Yield | 0.47% |
| Profit Margin | 31.94% |
| Operating Margin (TTM) | 19.94% |
| Diluted EPS (TTM) | 39.36 |
| Quarterly Revenue Growth (YOY) | -3.70% |
| Quarterly Earnings Growth (YOY) | 12.00% |
| Total Debt/Equity (MRQ) | 9.20% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | 3.95 B |
| Levered Free Cash Flow (TTM) | 2.08 B |
| Return on Assets (TTM) | 6.91% |
| Return on Equity (TTM) | 15.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Regeneron Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.13 |
|
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Value |
| % Held by Insiders | 1.89% |
| % Held by Institutions | 91.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 1,057.00 (Canaccord Genuity, 40.27%) | Buy |
| Median | 834.00 (10.68%) | |
| Low | 660.00 (UBS, -12.42%) | Hold |
| Average | 829.30 (10.05%) | |
| Total | 6 Buy, 4 Hold | |
| Avg. Price @ Call | 741.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 02 Feb 2026 | 818.00 (8.55%) | Buy | 749.55 |
| 08 Jan 2026 | 820.00 (8.82%) | Buy | 801.01 | |
| Evercore ISI Group | 22 Jan 2026 | 875.00 (16.12%) | Buy | 755.51 |
| B of A Securities | 07 Jan 2026 | 860.00 (14.13%) | Buy | 812.27 |
| Morgan Stanley | 12 Dec 2025 | 768.00 (1.92%) | Hold | 741.29 |
| 03 Dec 2025 | 767.00 (1.78%) | Hold | 723.67 | |
| Wells Fargo | 10 Dec 2025 | 745.00 (-1.13%) | Hold | 726.21 |
| 20 Nov 2025 | 700.00 (-7.11%) | Hold | 737.00 | |
| BMO Capital | 04 Dec 2025 | 850.00 (12.80%) | Buy | 722.80 |
| Canaccord Genuity | 04 Dec 2025 | 1,057.00 (40.27%) | Buy | 722.80 |
| HSBC | 24 Nov 2025 | 890.00 (18.11%) | Buy | 761.45 |
| Scotiabank | 24 Nov 2025 | 770.00 (2.18%) | Hold | 761.45 |
| UBS | 07 Nov 2025 | 660.00 (-12.41%) | Hold | 657.53 |
| Show more | ||||
No data within this time range.
| TTM Dividend Yield | 0.47% |
| 1Y Average Dividend Yield | 0.46% |
| Payout Ratio | 2.24% |
| Expected Next Dividend Payment | Mar 2026 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 20 Nov 2025 | - | 05 Dec 2025 | 0.88 Cash |
| 18 Aug 2025 | - | 03 Sep 2025 | 0.88 Cash |
| 20 May 2025 | - | 06 Jun 2025 | 0.88 Cash |
| 20 Feb 2025 | - | 20 Mar 2025 | 0.88 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 3.52 | 4 | 0.46 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |